SYNTHROID (levothyroxine sodium) by AbbVie is synthesis. First approved in 2002.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
SYNTHROID (levothyroxine sodium) is a synthetic thyroid hormone replacement therapy administered orally as a tablet. It treats hypothyroidism by replacing deficient T4, which is peripherally converted to the active T3 form to restore normal thyroid hormone signaling in cell nuclei and regulate metabolism, growth, and development.
A mature, high-volume asset nearing loss of exclusivity with significant defensive requirements and potential for generic competition impact on team structure.
synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form
Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
Worked on SYNTHROID at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
$355M Medicare spend — this is a commercially significant brand
Working on SYNTHROID at LOE approaching offers experience in defensive brand strategies, generic competition management, and customer value propositions beyond pure clinical efficacy. Roles emphasize access, formulary positioning, and market share protection rather than innovation or launch execution.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo